

## SUPPLEMENTAL MATERIAL

**Supplemental Table I** – Selective reaction monitoring (SRM) transitions for acyl carnitine analysis

<b>Acyl Carnitine</b>	<b>Transition, m/z</b>	<b>Retention Time</b>
<sup>12</sup> C acetyl (C2)	204.1→85	1.50-1.51
<sup>13</sup> C acetyl (C2)	205.1→85	1.50-1.51
Acetyl-d <sub>3</sub> -carnitine (internal standard)	207.1→85	1.50-1.51
<sup>12</sup> C butyryl (C4)	232.1→85	5.35-5.36
<sup>13</sup> C butyryl (C4)	234.1→85	5.35-5.36
<sup>12</sup> C 3-hydroxybutyryl- L (L-C4OH)	248.1→85	2.43-2.44
<sup>13</sup> C 3-hydroxybutyryl- L (L-C4OH)	250.1→85	2.43-2.44
<sup>12</sup> C 3-hydroxybutyryl- D (D-C4OH)	248.1→85	2.94-2.95
<sup>12</sup> C 3-hydroxybutyryl- D (D-C4OH)	250.1→85	2.94-2.95

## Supplemental Table II – Patient characteristics

Data shown are means  $\pm$  standard error of the mean


<b>Variables</b>	<b>Control (n=5)</b>	<b>Non-ischemic cardiomyopathy (n=5)</b>	<b>p-value</b>
Age at heart tissue acquisition, years	41 $\pm$ 8	46 $\pm$ 4	0.58
Male sex, n (%)	5 (100)	5 (100)	0.99
White or Caucasian race, n (%)	5 (100)	5 (100)	0.99
Body mass index, Kg/m <sup>2</sup>	27 $\pm$ 1	29 $\pm$ 3	0.58
Diabetes mellitus, n (%)	0 (0)	0 (0)	0.99
Left ventricular ejection fraction, %	67 $\pm$ 3	16 $\pm$ 4	<0.0001
Left ventricular end-diastolic diameter, cm	4.5 $\pm$ 0.3	7.3 $\pm$ 0.4	<0.001
Cardiac index, L/min/m <sup>2</sup>	4.1 $\pm$ 0.5	1.8 $\pm$ 0.2	<0.01

**Supplemental Table III – Antibodies used for Western Blotting**


<b>Antibody</b>	<b>Vendor</b>	<b>Catalogue</b>
Acyl CoA synthetase medium chain family member 3 (ACSM3)	Proteintech	10168-2-AP
$\beta$ -hydroxybutyrate dehydrogenase 1 (BDH1)	Proteintech	15417-1-AP
Calsequestrin (CASQ)	ThermoFisher	PA1-913
Carnitine palmitoyl transferase 1a (CPT1a)	Abcam	Ab128568
Carnitine palmitoyl transferase 1b (CPT1b)	Proteintech	22170-1-AP
Short chain acyl CoA dehydrogenase (SCAD)	GeneTex	GTX55489

**Supplemental Table IV – Primer sequences for mRNA analysis**

Gene	Primer Sequence
$\beta$ -hydroxybutyrate dehydrogenase 1 (BDH1) rat	Forward: AGG CTG TGA CTC TGG ATT TG Reverse: AGC ATC GCC TTT GTC CTT
$\beta$ -hydroxybutyrate dehydrogenase 1 (BDH1) human	TaqMan assay catalogue number Hs00366297_m1
Short chain acyl CoA dehydrogenase (SCAD) rat	Forward: CTC GAG ATT GGC GAA GAT TAC A Reverse: CAG CTC CTT CTC AGC AAA GT
Short chain acyl CoA dehydrogenase (SCAD) human	TaqMan assay catalogue number Hs00163506_m1



**Supplemental Figure I – The enrichment of short chain acyl carnitine species with  $^{13}\text{C}$  labelled carnitine.** Short chain carnitine species were measured by LC/MS and the enrichment of the pool with  $^{13}\text{C}$  carnitine species was determined. **A**, A depiction of the different short chain carnitine pools and their origination within the oxidative pathway for ketones and SCFA. **B**, Mean enrichment data for the different short chain carnitine pools with  $^{13}\text{C}$  labeled carnitine species is shown \* $p=0.0029$ , † $p<0.0001$ , ‡ $p<0.008$ , †† $p<0.0001$ , ‡‡ $p<0.0001$ , # $p=0.0022$ , \*\* $p=0.0035$  with comparisons as indicated via 2-way ANOVA and Tukey's post hoc test measured in hearts perfused with either  $^{13}\text{C}$  butyrate (n=7 sham, n=6 TAC) or  $^{13}\text{C}$  3-OHB (n=6 sham, n=6 TAC).



**Supplemental Figure II – The phosphorylation of AMPK (pAMPK) and total AMPK measured in hearts after perfusion with either the SCFA butyrate or the ketone 3-hydroxybutyrate (3-OHB). Hearts were perfused 14 weeks after TAC or sham surgery. \* $p < 0.05$  vs. butyrate sham and 3-OHB sham via 2-way ANOVA and Tukey's post hoc test,  $n=3$  for all groups.**